CAL
CTKB icon

Capital Advisors Ltd’s Cytek Biosciences CTKB Stock Holding History

Capital Advisors Ltd’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-39
Closed – – 1388
2024
Q4 		$0 Hold
39
– – ﹤0.01% 1413
2024
Q3 		$0 Hold
39
– – ﹤0.01% 1420
2024
Q2 		$0 Hold
39
– – ﹤0.01% 1428
2024
Q1 		$0 Hold
39
– – ﹤0.01% 1387
2023
Q4 		$0 Buy
+39
New +$245 ﹤0.01% 1326

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital Advisors Ltd's CTKB Position: Q1 2025 in Review

Capital Advisors Ltd sold out of Cytek Biosciences (CTKB) in Q1 2025, closing a stake of 39 shares.

Capital Advisors Ltd first reported a position in CTKB in Q4 2023 and held it in 5 quarters. The position peaked at $0 in Q4 2024. 160 funds tracked by Wall St. Rank hold CTKB as of Q1 2025.

  • Capital Advisors Ltd reported no remaining Cytek Biosciences position as of Q1 2025 after selling out during the quarter.
  • Capital Advisors Ltd sold 39 Cytek Biosciences shares in Q1 2025.
  • Capital Advisors Ltd first reported a position in Cytek Biosciences in Q4 2023 and held it in 5 quarters.
  • Capital Advisors Ltd's Cytek Biosciences position peaked at $0 in Q4 2024.
  • 160 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2025.

Based on Capital Advisors Ltd's 13F filing for Q1 2025, filed 15 Apr 2025.